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Background
An initial Delphi survey delineated key commonalities for a standard definition of clinical remission and inactive disease in jSLE. However, several additional clarifications were still required.
Objective
To develop a definition and criteria of clinical remission and inactive disease in jSLE.
Methods
A second international Delphi survey was conducted among pediatric rheumatologists. Consensus was set at 75%.
Results
There were 210 respondents. Consensus was achieved regarding the key definitions under consideration (Table  1) . Respondents also agreed that a) there should be at most one mild, non-limiting symptom; and b) there can be regular use of several systemic medications in clinical remission. There was no consensus on whether select laboratory tests could be abnormal, and whether regular use of non-steroidal anti-inflammatory drugs with clinical remission was permissible.
Conclusions
Consensus has been reached on the definition of 'Clinical Remission' and 'Clinically Inactive Disease' in jSLE. 
